You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 5,763,454

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,763,454

Title:	Crystal form of anhydrous 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-f luoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt
Abstract:	The anhydrate of 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt has advantageous stability for formulation as an antibacterial agent.
Inventor(s):	Handanyan; Lynne A. (New York, NY), Morris; Thomas A. (New York, NY), Hendrickson; Robert L. (New York, NY), Johnson; Phillip J. (New York, NY), Norris; Timothy (New York, NY)
Assignee:	Pfizer, Inc. (New York, NY)
Application Number:	08/849,300
Patent Claims:	1. 7-([1. alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluoro-1-( 2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt characterized by the following major peaks in its X-ray powder diffraction pattern 2. A process for preparing the compound according to claim 1, which comprises heating 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt or its derived monohydrate in the presence of an alcohol or mixture thereof with an aprotic co-solvent. 3. A pharmaceutical composition having antibacterial activity, which comprises crystalline 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt characterized by the following major peaks in its X-ray powder diffraction pattern 4. A method of treating a bacterial infection, which comprises administering to a subject in need of treatment an antibacterial amount of crystalline 7-([1.alpha.,5.alpha.,6.alpha.]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-flu oro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt characterized by the following major peaks in its X-ray powder diffraction pattern

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.